What is Multiple System Atrophy (MSA)?
Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disease that affects several vital systems in the body. It damages areas of the brain that control movement, balance, coordination, and automatic bodily functions such as blood pressure, bladder control, and digestion.
MSA is classified as an atypical parkinsonian disorder because many people initially develop symptoms similar to Parkinson’s disease, such as stiffness, slowed movement, and problems with walking. However, MSA progresses differently and also causes widespread problems with the autonomic nervous system—the system responsible for regulating functions that occur automatically in the body.
One of the most characteristic features of MSA is autonomic failure, which can include severe drops in blood pressure when standing (orthostatic hypotension), urinary problems, sexual dysfunction, and difficulties regulating heart rate, sweating, or body temperature.
Doctors generally recognize two main clinical forms of MSA:
• MSA-P (Parkinsonian type) – where symptoms resemble Parkinson’s disease, including rigidity and slowed movement.
• MSA-C (Cerebellar type) – where problems with balance, coordination, and speech are more prominent.
MSA is considered a synucleinopathy, meaning it is associated with the abnormal buildup of a protein called alpha-synuclein in certain brain cells. This abnormal protein accumulation leads to progressive damage in multiple brain regions that regulate movement and autonomic functions.
MSA is a prime of life disorder, typically symptoms occur when a person is in their mid-50s or early 60s, and symptoms gradually worsen over time. As the disease progresses, individuals may develop increasing difficulty with walking, speaking, swallowing, and maintaining blood pressure. Life expectancy after the onset of symptoms is usually between five and ten years, although the course of the disease can vary widely patient to patient.
Currently, there is no cure for MSA, and treatment focuses on managing symptoms and improving quality of life through medications, supportive therapies, and multidisciplinary care.
Because MSA is rare and often misdiagnosed in its early stages, raising awareness, improving diagnosis, and advancing research are essential to improving outcomes for people affected by this devastating disease.
